UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics prima…
$303.47+1.22%
报价 2026-11-06
市值
$2.35B
EV
$2.63B
PE (TTM)
33.3x
预期 PE (FY2026)
31.1x
52 周区间距高点 -9.4%
$185.45$334.84
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 10.28 → 10.85（1.1x） | 28.0 |
| FY+32028-12 | 1.2x | 10.28 → 12.77（1.2x） | 23.8 |
毛利率 29% · TTM 收入 $650M · 基数 EPS 10.28（调整后）
电话会信号
辅助标签Q3 20262026-11-04
扩产
指引 无
信心 4
分析师 4
“Robotic surgical platforms gaining adoption will see meaningful contribution in 2027 and beyond.”
原文引用（1）
- 扩产：At DAS Medical, we are adding capacity ahead of anticipated double-digit growth.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| UFPTUFP Technologies, Inc. | $2.35B | +1.2% | +9.1% | 29.3% | 33.3x | 22.8x | 41.6x | |
| PGNYProgyny, Inc. | $2.67B | +1.4% | +7.6% | 24.5% | 30.3x | 18.4x | 12.2x | |
| SDGRSchrödinger, Inc. | $2.23B | +3.6% | -4.3% | 59.3% | – | – | – | |
| IMNMImmunome, Inc. | $2.21B | +4.5% | -67.5% | -1,161.9% | – | – | – | |
| ESTAEstablishment Labs Holdings Inc. | $2B | +4.0% | +30.6% | 69.1% | – | – | – | 高增长 |
| ALVOAlvotech | $1.73B | +6.8% | +1.1% | 50.7% | – | – | – | |
| OMCLOmnicell, Inc. | $1.7B | -1.8% | +3.8% | 44.8% | 38.3x | 10.5x | 11.7x | |
| CNMDCONMED Corporation | $1.53B | -2.5% | -0.4% | 56.4% | 21.3x | 10.9x | 11.6x | |
| AHCOAdaptHealth Corp. | $999.4M | -1.1% | -10.8% | 15.4% | – | 36.8x | 12.2x | |
| 同行中位数 | – | – | +0.3% | 47.7% | 30.3x | 14.6x | 12.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $174M | $154.2M | $148.9M | $154.6M | $151.2M | $148.1M | $144.1M | $145.2M |
| Gross Margin | 29.3% | 28.8% | 28.2% | 27.7% | 28.8% | 28.5% | 29.2% | 28.6% |
| Operating Margin | 16.2% | 15.1% | 14.4% | 15.1% | 16.1% | 15.6% | 15.4% | 17.1% |
| Net Income | $20.9M | $17.5M | $17.6M | $16.4M | $17.2M | $17.2M | $16.4M | $16.4M |
| Diluted EPS | 2.68 | 2.24 | 2.24 | 2.11 | 2.21 | 2.21 | 2.1 | 2.11 |
| Operating Cash Flow | $15.6M | $3.2M | $16.8M | $35.9M | $25.3M | $13.8M | $24.4M | $19.8M |